Patents by Inventor Marie-Claire Wilson

Marie-Claire Wilson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fused aromatic PTP-1B inhibitors
    Patent number: 9334295
    Abstract: The invention encompasses the novel class of compounds represented by the formula below, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions which include the compounds shown (Formula I) above and methods of treating or preventing PTP-1B mediated diseases, including diabetes.
    Type: Grant
    Filed: October 28, 2014
    Date of Patent: May 10, 2016
    Assignee: KANEQ PHARMA INC.
    Inventors: John Colucci, Marie-Claire Wilson, Yongxin Han, Claude Dufresne, Michel Belley, Cheuk K. Lau, Christopher Bayly
  • FUSED AROMATIC PTP-1B INHIBITORS
    Publication number: 20150045325
    Abstract: The invention encompasses the novel class of compounds represented by the formula below, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions which include the compounds shown (Formula I) above and methods of treating or preventing PTP-1B mediated diseases, including diabetes.
    Type: Application
    Filed: October 28, 2014
    Publication date: February 12, 2015
    Applicant: Kaneq Pharma Inc.
    Inventors: John Colucci, Marie-Claire Wilson, Yongxin Han, Claude Dufresne, Michel Belley, Cheuk K. Lau, Christopher Bayly
  • FUSED AROMATIC PTP-1B INHIBITORS
    Publication number: 20130281365
    Abstract: The invention encompasses the novel class of compounds represented by the formula below, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions which include the compounds shown (Formula I) above and methods of treating or preventing PTP-1B mediated diseases, including diabetes.
    Type: Application
    Filed: July 12, 2013
    Publication date: October 24, 2013
    Inventors: John COLUCCI, Marie-Claire WILSON, Yongxin HAN, Claude DUFRESNE, Michel BELLEY, Cheuk K. LAU, Christopher BAYLY
  • Fused aromatic PTP-1B inhibitors
    Patent number: 8481742
    Abstract: The invention encompasses the novel class of compounds represented by the formula below, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions which include the compounds shown (Formula I) above and methods of treating or preventing PTP-1B mediated diseases, including diabetes.
    Type: Grant
    Filed: March 13, 2012
    Date of Patent: July 9, 2013
    Assignee: Kaneq Pharma Inc.
    Inventors: John Colucci, Marie-Claire Wilson, Yongxin Han, Claude Dufresne, Michel Belley, Cheuk K. Lau, Christopher Bayly
  • FUSED AROMATIC PTP-IB INHIBITORS
    Publication number: 20120178679
    Abstract: The invention encompasses the novel class of compounds represented by the formula below, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions which include the compounds shown (Formula I) above and methods of treating or preventing PTP-1B mediated diseases, including diabetes.
    Type: Application
    Filed: March 13, 2012
    Publication date: July 12, 2012
    Applicant: KANEQ PHARMA INC.
    Inventors: John COLUCCI, Marie-Claire WILSON, Yongxin HAN, Claude DUFRESNE, Michel BELLEY, Cheuk K. LAU, Christopher BAYLY
  • Fused aromatic PTP-1B inhibitors
    Patent number: 8168815
    Abstract: The invention encompasses the novel class of compounds represented by the formula below, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions which include the compounds shown (Formula I) above and methods of treating or preventing PTP-1B mediated diseases, including diabetes.
    Type: Grant
    Filed: January 24, 2008
    Date of Patent: May 1, 2012
    Assignee: Kaneq Pharma Inc.
    Inventors: John Colucci, Marie-Claire Wilson, Yongxin Han, Claude Dufresne, Michel Belley, Cheuk K. Lau, Christopher Bayly
  • EP4 Receptor Agonist, Compositions and Methods Thereof
    Publication number: 20110237511
    Abstract: This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.
    Type: Application
    Filed: June 3, 2011
    Publication date: September 29, 2011
    Applicant: Merck Frosst Canada
    Inventors: Xavier Billot, John Colucci, Yongxin Han, Marie-Claire Wilson, Robert N. Young
  • FUSED AROMATIC PTP-1B INHIBITORS
    Publication number: 20100022477
    Abstract: The invention encompasses the novel class of compounds represented by the formula below, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions which include the compounds shown (Formula I) above and methods of treating or preventing PTP-1B mediated diseases, including diabetes.
    Type: Application
    Filed: January 24, 2008
    Publication date: January 28, 2010
    Inventors: John Colucci, Marie-Claire Wilson, Yongxin Han, Claude Dufresne, Michel Belley, Cheuk K. Lau, Christopher Bayly
  • EPreceptor agonist, compositions and methods thereof
    Patent number: 7238710
    Abstract: This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.
    Type: Grant
    Filed: June 7, 2005
    Date of Patent: July 3, 2007
    Assignee: Merck Frosst Canada, Ltd.
    Inventors: Xavier Billot, John Colucci, Yongxin Han, Marie-Claire Wilson, Robert N. Young
  • EP4 receptor agonist, compositions and methods thereof
    Publication number: 20060270721
    Abstract: This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.
    Type: Application
    Filed: August 2, 2006
    Publication date: November 30, 2006
    Inventors: Yongxin Han, John Colucci, Xavier Billot, Marie-Claire Wilson, Robert Young
  • Oxazolidin-2-one and thiazolidin-2-one derivatives for use as EPreceptor agonists in the treatment of glaucoma
    Patent number: 7109223
    Abstract: This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.
    Type: Grant
    Filed: August 25, 2003
    Date of Patent: September 19, 2006
    Assignee: Merck & Co. Inc.
    Inventors: Yongxin Han, John Colucci, Xavier Billot, Marie-Claire Wilson, Robert Young
  • Ep4 receptor agonists
    Publication number: 20060167081
    Abstract: This invention relates to potent selective agonists of the EP, subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.
    Type: Application
    Filed: October 23, 2003
    Publication date: July 27, 2006
    Inventors: Xavier Billot, Jean-Luc Beaunard, Yongxin Han, Robert Young, John Colucci, Mario Girard, Marie-Claire Wilson
  • Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
    Publication number: 20060154899
    Abstract: This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.
    Type: Application
    Filed: August 25, 2003
    Publication date: July 13, 2006
    Inventors: Yongxin Han, John Colucci, Xavier Billot, Marie-Claire Wilson, Robert Young
  • EP receptor agonist, compositions and methods thereof
    Patent number: 7053085
    Abstract: This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.
    Type: Grant
    Filed: March 10, 2004
    Date of Patent: May 30, 2006
    Assignee: Merck & Co. Inc.
    Inventors: Xavier Billot, John Colucci, Yongxin Han, Marie-Claire Wilson, Robert N. Young
  • EP4 receptor agonist, compositions and methods thereof
    Publication number: 20050227969
    Abstract: This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.
    Type: Application
    Filed: June 7, 2005
    Publication date: October 13, 2005
    Inventors: Xavier Billot, John Colucci, Yongxin Han, Marie-Claire Wilson, Robert Young
  • EP4 receptor agonist, compositions and methods thereof
    Publication number: 20040198701
    Abstract: This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.
    Type: Application
    Filed: March 10, 2004
    Publication date: October 7, 2004
    Inventors: Xavier Billot, John Colucci, Yongxin Han, Marie-Claire Wilson, Robert N. Young
  • Method for synthesizing oxazinones
    Publication number: 20030232820
    Abstract: New methods and intermediates are discussed for the stereospecific synthesis of oxazinone compounds.
    Type: Application
    Filed: August 29, 2002
    Publication date: December 18, 2003
    Inventors: Saul Wolfe, Marie-Claire Wilson, Ming-Huei Cheng
  • EPreceptor agonist, compositions and methods thereof
    Patent number: RE42562
    Abstract: This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.
    Type: Grant
    Filed: April 26, 2007
    Date of Patent: July 19, 2011
    Assignee: Merck Frosst Canada
    Inventors: Xavier Billot, John Colucci, Robert N. Young, Yongxin Han, Marie-Claire Wilson